Merck to Present Rebif® (interferon beta-1a) and Investigational Cladribine Tablets Data at AAN 2017

Darmstadt, Germany (ots/PRNewswire) -

- Breadth of data and activities underscore company's long-standing
commitment to enhancing care for people with MS

Merck, a leading science and technology company, will present data
at the American Academy of Neurology (AAN) 69th Annual Meeting,
taking place from April 22-28, 2017, in Boston, Mass. Merck will
present 15 abstracts on multiple sclerosis (MS), including studies
evaluating Rebif® (interferon beta-1a) and investigational Cladribine
Tablets, as well as analyses of complications and MS relapse rates
during pregnancy and real-world data related to the impact of
treatment adherence and patient costs.

(Logo: http://mma.prnewswire.com/media/492737/Merck_Logo.jpg )

"Rebif has a well-established safety profile supported by more
than 20 years of accrued clinical trial and patient experience, and
the information from the studies and analyses we are presenting at
AAN deepens our understanding of this important RRMS therapy," said
Dr. Kathleen Hawker, Vice President, Neurology and Immunology US, EMD
Serono, the biopharmaceutical business of Merck KGaA, Darmstadt,
Germany.

The company will also present efficacy and safety data for
Cladribine Tablets, an investigational short-course oral therapy that
is thought to selectively and periodically target lymphocytes which
may be integral to the pathological process of MS. Cladribine Tablets
is currently under clinical investigation and not yet approved for
the treatment for any use in the United States, Canada or elsewhere.
In July 2016, the European Medicines Agency (EMA) accepted for review
the Marketing Authorisation Application (MAA) of Cladribine Tablets
for the treatment of adult patients with RRMS.

"We have an unwavering focus on delivering innovation to patients
in need, and our presentations this week at AAN, a leading neurology
conference, further validate the promise of Cladribine Tablets as a
potential RRMS treatment option," said Luciano Rossetti, Head of
Global R&D for the biopharma business of Merck.

Attendees can learn more about our programs, pipeline and
activities in neurology by visiting our medical booth #473. Booth
activities include a $25,000 charitable donation presentation to Can
DO MS on April 25 at 3 p.m., as well as "I'm Facing MS" simulation
stations that will translate users' experiences with different MS
impairments into artwork.

AAN Brain Health Fair

EMD Serono, the biopharmaceutical business of Merck KGaA,
Darmstadt, Germany, in the US and Canada will have an exhibition at
the AAN Brain Health Fair on April 21 from 10 a.m. - 4 p.m. ET, where